PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34840266-3 2022 Treatment with rapamycin, the selective inhibitor of mTOR, initiated at the 4th week of DOCA-salt administration normalized the SBP and attenuated rpS6 activity in the heart, aorta, and kidney. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 53-57 34854520-13 2022 Additionally, the hypertrophic responses caused by miR-339-5p was alleviated in the presence of mTOR inhibitor rapamycin. Sirolimus 111-120 mechanistic target of rapamycin kinase Rattus norvegicus 96-100 34167449-7 2021 The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin. Sirolimus 97-106 mechanistic target of rapamycin kinase Rattus norvegicus 266-270 34167449-7 2021 The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin. Sirolimus 219-228 mechanistic target of rapamycin kinase Rattus norvegicus 266-270 34167449-7 2021 The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin. Sirolimus 339-348 mechanistic target of rapamycin kinase Rattus norvegicus 266-270 34859624-9 2021 RAPA could also enhance the relative protein expression of Beclin-1 and LC3-II (P<0.01), and reduce the expression of p-mTOR (P<0.01). Sirolimus 0-4 mechanistic target of rapamycin kinase Rattus norvegicus 120-124 26341392-6 2015 Indeed, the mTOR inhibitor rapamycin, and actinomycin-D, a transcription inhibitor, blocked the enhanced effects of LY39 on NMDAR-mEPSCs. Sirolimus 27-36 mechanistic target of rapamycin kinase Rattus norvegicus 12-16 34863087-5 2021 The proapoptotic effect of HG was rescued by either the Fyn inhibitor PP1 or the mTOR inhibitor rapamycin. Sirolimus 96-105 mechanistic target of rapamycin kinase Rattus norvegicus 81-85 34784444-4 2022 The present study investigated whether rapamycin can attenuate PND by inhibiting mTOR and activating autophagy in diabetic rats. Sirolimus 39-48 mechanistic target of rapamycin kinase Rattus norvegicus 81-85 34784444-11 2022 Pretreatment of rats with rapamycin inhibited mTOR hyperactivation and restored autophagic function, effectively decreasing tau hyperphosphorylation, Abeta deposition, and apoptosis in the hippocampus. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 46-50 34555398-13 2021 However, these effects on H9c2 cells were notably abolished by the PI3K inhibitor LY294002 and mTOR inhibitor rapamycin. Sirolimus 110-119 mechanistic target of rapamycin kinase Rattus norvegicus 95-99 34362635-10 2021 Although rapamycin (mTOR inhibitor) prevented this cardioprotective effect induced by Leu, wortmannin (PI3K inhibitor) did not interfere with this effect. Sirolimus 9-18 mechanistic target of rapamycin kinase Rattus norvegicus 20-24 34698133-2 2021 Rapamycin, an inhibitor of mTOR, was shown to stimulate beta-cell autophagy. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 27-31 34417329-4 2021 Intradermal administration of inhibitors of mTOR (Rapamycin) and Protein Kinase B (AKT; AKT inhibitor IV), signaling molecules downstream of PI3Kgamma, also attenuates HMWH-induced anti-hyperalgesia. Sirolimus 50-59 mechanistic target of rapamycin kinase Rattus norvegicus 44-48 34082015-17 2021 Furthermore, the effects of SZL on myelin proteins, p-Akt, and p-mTOR were clearly inhibited by LY294002 and/or rapamycin, antagonists of PI3K and m-TOR, respectively. Sirolimus 112-121 mechanistic target of rapamycin kinase Rattus norvegicus 65-69 34812711-4 2021 The mechanistic target of rapamycin is a central signaling pathway for coordination and control; the administration of rapamycin, a key modulator of this pathway, could be a new therapeutic approach in neurological disorders. Sirolimus 119-128 mechanistic target of rapamycin kinase Rattus norvegicus 4-35 34812711-10 2021 CONCLUSIONS: Pretreatment with Sertoli cell transplant plus rapamycin injection may enhance neural survival during ischemia through increased glial cell-derived neurotrophic factor and vascular endothelial growth factor, inhibiting the mechanistic target of rapamycin pathway and increasing autophagy performance. Sirolimus 60-69 mechanistic target of rapamycin kinase Rattus norvegicus 236-267 34374900-10 2021 And rapamycin, an mTOR inhibitor, completely inhibited the antidepressant-like activity of NBP in vivo. Sirolimus 4-13 mechanistic target of rapamycin kinase Rattus norvegicus 18-22 34102263-5 2021 The expression levels of the phosphorylated p70S6K, a downstream molecule of mTOR, in the proximal and distal stumps of the transected IAN were significantly reduced by rapamycin administration to the injured site. Sirolimus 169-178 mechanistic target of rapamycin kinase Rattus norvegicus 77-81 34278477-10 2021 Notably, the rapamycin-mediated suppression of phosphorylated-mTOR, and elevation of Beclin 1 and LC3II expression in the rat hippocampus could not be alleviated by asiaticoside treatment. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 62-66 34494222-11 2021 Akt/mTOR/ p70S6K signaling cascade was proved to be present in NPCs, IGF-I overexpression significantly activated Akt/mTOR/p70S6K signaling cascade, while rapamycin addition inhibited its expression. Sirolimus 155-164 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 34533799-1 2021 OBJECTIVE: To investigate the pharmacodynamic mechanism of curcumin against myocardial ischaemia-reperfusion injury by regulating the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/rapamycin target protein (mTOR) signalling pathway. Sirolimus 194-203 mechanistic target of rapamycin kinase Rattus norvegicus 220-224 34242720-7 2021 Furthermore, Rapa pretreatment antagonized MeHg-induced apoptosis, whereas 3-MA further aggravated apoptosis, which were supported by findings that Rapa activated mTOR-mediated autophagy while 3-MA inhibited Vps34-related autophagy, further affect neuronal apoptosis through regulation of apoptotic factors mentioned above. Sirolimus 13-17 mechanistic target of rapamycin kinase Rattus norvegicus 163-167 34242720-7 2021 Furthermore, Rapa pretreatment antagonized MeHg-induced apoptosis, whereas 3-MA further aggravated apoptosis, which were supported by findings that Rapa activated mTOR-mediated autophagy while 3-MA inhibited Vps34-related autophagy, further affect neuronal apoptosis through regulation of apoptotic factors mentioned above. Sirolimus 148-152 mechanistic target of rapamycin kinase Rattus norvegicus 163-167 34354602-3 2021 Rapamycin, a first-generation mTOR inhibitor, produces divergent effects on neuronal survival and alteration in BBB disruption. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 30-34 35196893-6 2022 Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively. Sirolimus 27-36 mechanistic target of rapamycin kinase Rattus norvegicus 144-148 34222263-10 2021 To further investigate the role of P2X7 in OA, we injected mTOR antagonist rapamycin or P2X7 antagonist A740003 into the knee joints of ACLT rats. Sirolimus 75-84 mechanistic target of rapamycin kinase Rattus norvegicus 59-63 34177589-8 2021 Moreover, the CGGD-containing serum also decreased LC3B or collagen I expression after rapamycin (mTOR inhibitor) or SP600125 (JNK inhibitor) treatment in PSCs. Sirolimus 87-96 mechanistic target of rapamycin kinase Rattus norvegicus 98-102 34074073-0 2021 (Rapamycin activates autophagy by inhibiting mTOR pathway to alleviate early osteoporosis in rats with skeletal fluorosis). Sirolimus 1-10 mechanistic target of rapamycin kinase Rattus norvegicus 45-49 34074073-1 2021 Objective: To investigate the effects of rapamycin target protein (mTOR) pathway and autophagy on bone formation and bone resorption in fluorosis osteoporosis in rats. Sirolimus 41-50 mechanistic target of rapamycin kinase Rattus norvegicus 67-71 34074073-14 2021 Conclusion: RAPA may activate autophagy by inhibiting mTOR phosphorylation, and inhibit bone resorption while promoting bone formation, thus alleviating early osteoporosis in skeletal fluorosis rats. Sirolimus 12-16 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 35623563-6 2022 As an mTOR inhibitor, Rap induced autophagy and inhibited NF-kappaB-mediated pro-inflammatory signaling. Sirolimus 22-25 mechanistic target of rapamycin kinase Rattus norvegicus 6-10 35438806-8 2022 Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning. Sirolimus 135-144 mechanistic target of rapamycin kinase Rattus norvegicus 50-54 35438806-8 2022 Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning. Sirolimus 135-144 mechanistic target of rapamycin kinase Rattus norvegicus 170-174 35438806-8 2022 Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning. Sirolimus 135-144 mechanistic target of rapamycin kinase Rattus norvegicus 274-278 34322484-3 2021 Application of rapamycin, a specific inhibitor of mTOR, attenuated the phosphorylation of S6 and 4E-BP1 and as such, largely inhibited the mechanical activation of mTOR. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 50-54 34322484-3 2021 Application of rapamycin, a specific inhibitor of mTOR, attenuated the phosphorylation of S6 and 4E-BP1 and as such, largely inhibited the mechanical activation of mTOR. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 164-168 34064854-9 2021 Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 43-47 35196893-6 2022 Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively. Sirolimus 38-42 mechanistic target of rapamycin kinase Rattus norvegicus 144-148 35446876-0 2022 The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 35446876-2 2022 The mTOR inhibitor Rapamycin protects from senescence in experimental models, but its antiproliferative properties have raised concern early after transplantation particularly at higher doses. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 35446876-9 2022 mTOR inhibition with low-dose Rapamycin in the immediate posttransplant period protected from premature cellular senescence without negative effects on structural and functional recovery from preservation/reperfusion damage, glucose homeostasis, and growth in a rat kidney transplantation model. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 35133561-8 2022 Furthermore, Ang II-induced loss of autophagy and promotion of apoptosis in CFs were prevented by the treatment with Pyr1-apelin-13 or AMPK agonist AICAR or mTOR inhibitor rapamycin, respectively. Sirolimus 172-181 mechanistic target of rapamycin kinase Rattus norvegicus 157-161 35197970-0 2022 Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 104-108 35197970-12 2022 Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 27-31 35197970-12 2022 Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 67-71 35197970-13 2022 In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity. Sirolimus 39-48 mechanistic target of rapamycin kinase Rattus norvegicus 189-193 35587661-4 2022 After establishment, group C was injected pcDNA3.1-miR-100-5p recombinant plasmid, group D was injected mTOR inhibitor rapamycin, group E was injected with pcDNA3.1-miR-100-5p recombinant plasmid and rapamycin, and group A was injected same amount of normal saline in the same way. Sirolimus 119-128 mechanistic target of rapamycin kinase Rattus norvegicus 104-108 34874016-11 2022 Our findings also support the standpoint that the mTOR inhibitor, rapamycin, can eliminate T-induced cardiomyocyte hypertrophy. Sirolimus 66-75 mechanistic target of rapamycin kinase Rattus norvegicus 50-54 35048147-16 2022 Additionally, p-mTOR expression was significantly reduced in groups that rapamycin was injected. Sirolimus 73-82 mechanistic target of rapamycin kinase Rattus norvegicus 16-20 33278393-6 2021 Additionally, the mechanism by which prolonged CI affected autophagy was investigated through determination of the molecules related to the mTOR pathway after treatment with 3-Methyladenine (3-MA), rapamycin and an adenosine triphosphate (ATP) synthase inhibitor oligomycin (OM). Sirolimus 198-207 mechanistic target of rapamycin kinase Rattus norvegicus 140-144 34021461-10 2021 Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells. Sirolimus 105-114 mechanistic target of rapamycin kinase Rattus norvegicus 95-99 33930202-16 2021 Our results showed that the inhibitory effect of mTOR inhibitor (rapamycin) on reactive oxygen species production during NLRP3 inflammasome activation could bring about behavioral alterations in anxiety and depression. Sirolimus 65-74 mechanistic target of rapamycin kinase Rattus norvegicus 49-53 33641344-5 2021 Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 33285202-0 2021 Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin. Sirolimus 113-122 mechanistic target of rapamycin kinase Rattus norvegicus 98-102 33285202-5 2021 We could show that treatment with rapamycin diminished GBM tumor growth, confirming mTOR-signaling as one key driver for tumor growth. Sirolimus 34-43 mechanistic target of rapamycin kinase Rattus norvegicus 84-88 33278579-5 2021 Rapamycin (RM) was also used to treat animals as an mTOR inhibitor. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 33988537-12 2021 To further investigate the function of PPARalpha in sepsis, we inhibited mTOR with rapamycin and examined mitochondrial injury and ROS levels. Sirolimus 83-92 mechanistic target of rapamycin kinase Rattus norvegicus 73-77 33897438-0 2021 Disrupting Reconsolidation by Systemic Inhibition of mTOR Kinase via Rapamycin Reduces Cocaine-Seeking Behavior. Sirolimus 69-78 mechanistic target of rapamycin kinase Rattus norvegicus 53-57 33383488-13 2021 Overexpression of PI3K, AKT and mTOR were suppressed by RAPA treatment. Sirolimus 56-60 mechanistic target of rapamycin kinase Rattus norvegicus 32-36 33383488-16 2021 We proposed a potential mechanism that RAPA may play improving role by inhibiting neuronal apoptosis and enhancing mitophagy through PI3K/AKT/mTOR pathway. Sirolimus 39-43 mechanistic target of rapamycin kinase Rattus norvegicus 142-146 33598769-7 2021 However, Akt and mTOR inhibitors (MK-2206 and Rapamycin) blocked the effect of taurine on improving axonal damage. Sirolimus 46-55 mechanistic target of rapamycin kinase Rattus norvegicus 17-21 33530801-1 2021 OBJECTIVE: To investigate the effects of 1,25(OH)2D3 on renal fibrosis associated with the AMP-activated protein kinase (AMPK)alpha/mechanistic target of rapamycin (mTOR) signalling pathway in a rat model of unilateral ureteral obstruction (UUO). Sirolimus 154-163 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 33479328-0 2021 Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin. Sirolimus 99-108 mechanistic target of rapamycin kinase Rattus norvegicus 83-87 33479328-1 2021 Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Sirolimus 44-53 mechanistic target of rapamycin kinase Rattus norvegicus 28-32 32949703-12 2020 The effects by THP on lung injury, PI3K/AKT/mTOR signaling and autophagy were also observed after treatment with 3-MA, an autophagy inhibitor, whereas were blocked by combinational treatment with RAPA, an autophagy inducer. Sirolimus 196-200 mechanistic target of rapamycin kinase Rattus norvegicus 44-48 33130049-2 2020 This study, hence, examined whether treatment with Art alone or in combination with rapamycin (Rapa), an mTOR inhibitor, can ameliorate hepatic I/R injury via targeting the NLRP3 inflammasome signaling pathway. Sirolimus 95-99 mechanistic target of rapamycin kinase Rattus norvegicus 105-109 33075479-8 2020 We observed that intracerebral-ventricular administration of the mTOR inhibitor rapamycin reduced immunoreactivity of phosphorylated S6, a downstream target of mTOR, in brain regions involved in fear extinction and eliminated the enhancement of fear extinction memory produced by acute exercise, without reducing voluntary exercise behavior or altering fear extinction in sedentary rats. Sirolimus 80-89 mechanistic target of rapamycin kinase Rattus norvegicus 65-69 33075479-8 2020 We observed that intracerebral-ventricular administration of the mTOR inhibitor rapamycin reduced immunoreactivity of phosphorylated S6, a downstream target of mTOR, in brain regions involved in fear extinction and eliminated the enhancement of fear extinction memory produced by acute exercise, without reducing voluntary exercise behavior or altering fear extinction in sedentary rats. Sirolimus 80-89 mechanistic target of rapamycin kinase Rattus norvegicus 160-164 33312358-12 2020 PI3K, p-AKT1, p-mTOR, p-p70S6K and caspase-3 were down-regulated by rapamycin and beta-ecdysterone, and up-regulated by 3-methyladenine in both the chondrocytes and the cartilage tissues. Sirolimus 68-77 mechanistic target of rapamycin kinase Rattus norvegicus 16-20 32712090-7 2020 Intrathecal injection of rapamycin (an mTOR inhibitor) or SRT1720 (an agonist of Sirt1) induced analgesia in BIP rats. Sirolimus 25-34 mechanistic target of rapamycin kinase Rattus norvegicus 39-43 33317171-5 2020 Interestingly, the pre-treatment with rapamycin, an mTOR inhibitor, further increased the expression levels of LC3-II induced by OGT inhibition, implicating the involvement of mTOR signaling in O-GlcNAcylation-dependent autophagy. Sirolimus 38-47 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 33317171-5 2020 Interestingly, the pre-treatment with rapamycin, an mTOR inhibitor, further increased the expression levels of LC3-II induced by OGT inhibition, implicating the involvement of mTOR signaling in O-GlcNAcylation-dependent autophagy. Sirolimus 38-47 mechanistic target of rapamycin kinase Rattus norvegicus 176-180 32798557-0 2020 Rapamycin improves renal injury induced by Iodixanol in diabetic rats by deactivating the mTOR/p70S6K signaling pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 90-94 32798557-10 2020 Moreover, Rapamycin could inhibit the phosphorylation of mTOR/p70S6K pathway-associated proteins, activate autophagy and increase the levels of LC3 and Beclin1. Sirolimus 10-19 mechanistic target of rapamycin kinase Rattus norvegicus 57-61 32798557-11 2020 After treatment with 3MA, an inhibitor of mTOR/p70S6K signaling pathway, the protective effects of Rapamycin on CIAKI were weakened. Sirolimus 99-108 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 32798557-12 2020 SIGNIFICANCE: Rapamycin can alleviate renal injury induced by Iodixanol diabetic rats, and its regulatory mechanisms may be related to the regulation of mTOR/p70S6K signaling pathway and the activating autophagy. Sirolimus 14-23 mechanistic target of rapamycin kinase Rattus norvegicus 153-157 32512114-2 2020 Here, we show that painful symptoms and associated cognitive deficits induced by spinal nerve ligation in the rat are prevented by the administration of serotonin 5-HT6 receptor inverse agonists or by the mTOR inhibitor rapamycin. Sirolimus 220-229 mechanistic target of rapamycin kinase Rattus norvegicus 205-209 32651677-2 2020 Moreover, we assessed whether inhibition of mTOR signaling pathway by rapamycin would protect primordial follicle reserve after ovarian tissue freezing/thawing and re-transplantation. Sirolimus 70-79 mechanistic target of rapamycin kinase Rattus norvegicus 44-48 32802135-10 2020 The ROS value was increased significantly after rapamycin inhibited mTOR (66.18 (+4.03 vs. 52.31 (+6.01), n = 3, P < 0.05). Sirolimus 48-57 mechanistic target of rapamycin kinase Rattus norvegicus 68-72 32642911-9 2020 Preincubation with the mTOR inhibitor rapamycin restored the autophagic flux and markedly reduced the adverse effects of HTG. Sirolimus 38-47 mechanistic target of rapamycin kinase Rattus norvegicus 23-27 32774416-10 2020 Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 41-45 32774416-10 2020 Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 111-115 32444657-0 2020 Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by rapamycin-sensitive mTOR complex 1 inhibition. Sirolimus 100-109 mechanistic target of rapamycin kinase Rattus norvegicus 120-124 32570711-8 2020 Inhibition of mTOR by rapamycin prevents and corrects the increased parathyroid cell proliferation of SHP. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 32462682-1 2020 The present study examined the potential of Zingiber officinale-Terminalia chebula extract alone (ZO and TC) and in combination (ZOTC) against type 2 diabetes via downregulation of mechanistic target of rapamycin (mTOR). Sirolimus 203-212 mechanistic target of rapamycin kinase Rattus norvegicus 214-218 32645638-2 2020 Rapamycin inhibits activity of immune cells through the mTOR signaling pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 56-60 32645638-5 2020 Overall, our findings suggest that rapamycin may act on immune functions not only directly by inhibiting of mTOR in immune cells but also indirectly via modulation of neuroendocrine system. Sirolimus 35-44 mechanistic target of rapamycin kinase Rattus norvegicus 108-112 31664701-8 2020 Rapamycin in the adulthood reversed iron-induced memory deficits, decreased the ratio phospho-mTOR/total mTOR, and recovered LC3 II levels in iron-treated rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 94-98 32378972-1 2021 Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively. Sirolimus 181-190 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 32378972-1 2021 Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively. Sirolimus 181-190 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 32378972-1 2021 Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively. Sirolimus 181-185 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 32378972-1 2021 Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively. Sirolimus 181-185 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 32378972-10 2021 No notable difference was manifested in PDTC pre-treatment group, while a prominent increase was shown after Rapa pre-administration.Conclusion: The administration of PDTC and Rapa could prevent IH-induced hippocampal neuron impairment, indicating that inhibition of the mTOR and NF-kappaB pathway may likely act as a therapeutic target for obstructive sleep apnea. Sirolimus 176-180 mechanistic target of rapamycin kinase Rattus norvegicus 271-275 32006902-11 2020 More importantly, we have shown that the protective effect of GRb1 against I/R injury induced cardiomyocyte apoptosis is associated with the activation of mTOR signal pathway as evident by the use of rapamycin. Sirolimus 200-209 mechanistic target of rapamycin kinase Rattus norvegicus 155-159 32395516-6 2020 Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02). Sirolimus 29-33 mechanistic target of rapamycin kinase Rattus norvegicus 234-238 31423743-8 2020 Mechanistically, our results demonstrated that autophagy activation by AMPK activator metformin or mTOR inhibitor rapamycin obviously promotes cell survival and autophagy flux, improved mitochondrial ultrastructure, and reduced expression of Cyt-C and caspase-3 in CORT-induced PC12 cells. Sirolimus 114-123 mechanistic target of rapamycin kinase Rattus norvegicus 99-103 32182210-6 2020 We also found that treatment with rapamycin (a selective mTOR inhibitor) also exerts chondro-protective effects that ameliorate OA by promoting autophagy. Sirolimus 34-43 mechanistic target of rapamycin kinase Rattus norvegicus 57-61 32104252-7 2020 However, treatment of rats with VD with NBP plus the mTOR inhibitor rapamycin failed to significantly suppress Beclin 1 and LC3II expression. Sirolimus 68-77 mechanistic target of rapamycin kinase Rattus norvegicus 53-57 31664701-8 2020 Rapamycin in the adulthood reversed iron-induced memory deficits, decreased the ratio phospho-mTOR/total mTOR, and recovered LC3 II levels in iron-treated rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 105-109 31638215-8 2019 In contrast, treatment with rapamycin, an mTOR inhibitor, produced the opposite phenotype. Sirolimus 28-37 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 31746373-0 2020 Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 117-121 31746373-2 2020 Rapamycin has been shown to be cardioprotective in pressure-overloaded and ischemic heart diseases by regulating the mechanistic target of rapamycin (mTOR) signaling network. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 117-148 31746373-2 2020 Rapamycin has been shown to be cardioprotective in pressure-overloaded and ischemic heart diseases by regulating the mechanistic target of rapamycin (mTOR) signaling network. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 150-154 31746373-14 2020 Rapamycin treatment for 4 weeks inhibited the mTOR and ER stress pathways. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 46-50 31746373-16 2020 These results demonstrated that rapamycin reduced cardiomyocyte apoptosis and promoted cardiomyocyte autophagy, by regulating the crosstalk between the mTOR and ER stress pathways in chronic HF. Sirolimus 32-41 mechanistic target of rapamycin kinase Rattus norvegicus 152-156 32399023-7 2020 Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 22-26 32399023-7 2020 Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 65-69 32399023-7 2020 Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 65-69 31782272-12 2020 Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 31782272-13 2020 CONCLUSIONS: Rapamycin may be useful for the treatment of hyperoxia-induced acute lung injury (ALI) by inhibiting the activation of mTOR signaling pathway. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 132-136 31693798-5 2020 Using behavioral tools and MRI-based functional imaging, together with biochemical and immunohistochemical approaches, we demonstrate that chronic mTOR attenuation with rapamycin ameliorates deficits in learning and memory, prevents neurovascular uncoupling, and restores cerebral perfusion in aged rats. Sirolimus 169-178 mechanistic target of rapamycin kinase Rattus norvegicus 147-151 31553625-10 2019 Treatment with mTOR inhibitor rapamycin effectively blocked nicotine-mediated autophagy deficiency and more importantly, reversed nicotine-induced increase in HI brain infarction. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 31152486-6 2019 TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho-mTOR, phospo-p70S6K, and phospo-S6. Sirolimus 8-12 mechanistic target of rapamycin kinase Rattus norvegicus 27-31 31152486-6 2019 TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho-mTOR, phospo-p70S6K, and phospo-S6. Sirolimus 8-12 mechanistic target of rapamycin kinase Rattus norvegicus 80-84 32042772-4 2019 Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay. Sirolimus 10-19 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 32042772-4 2019 Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay. Sirolimus 10-19 mechanistic target of rapamycin kinase Rattus norvegicus 189-193 32042772-4 2019 Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay. Sirolimus 21-25 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 32042772-4 2019 Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay. Sirolimus 21-25 mechanistic target of rapamycin kinase Rattus norvegicus 189-193 32042772-8 2019 Catalpol can also reversed proteins reduced by Rapa related with PI3K/AKT/mTOR pathway. Sirolimus 47-51 mechanistic target of rapamycin kinase Rattus norvegicus 74-78 31505123-6 2019 Treatment with rapamycin, a selective inhibitor of mTOR, reversed all the I/R-induced changes as manifested by its anti-inflammatory and antioxidant effects in kidney and gastrocnemius muscle of rats. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 31505123-7 2019 Collectively, these findings suggest that rapamycin protects against I/R-induced oxidative-nitrosative stress and inflammation leading to organ injuries via suppression of mTOR/IkappaB-alpha/NF-kappaB signaling pathway. Sirolimus 42-51 mechanistic target of rapamycin kinase Rattus norvegicus 172-176 31591945-3 2019 The possible mechanism of mTOR signaling pathway was evaluated by the, inhibitors for mTOR and PI3K, rapamycin and wortmannin, respectively. Sirolimus 101-110 mechanistic target of rapamycin kinase Rattus norvegicus 26-30 31591945-7 2019 However, only the phosphorylated level of mTOR decreased obviously after rapamycin administration. Sirolimus 73-82 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 31849609-7 2019 Treating neurons with either rapamycin to inhibit the mTOR or LY294002 to inhibit the PI3K/Akt activity rescued the morphological abnormalities resulting from either NL3 knockdown or knockout (KO). Sirolimus 29-38 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 31564412-0 2019 Prevention of post-ischemic seizure by rapamycin is associated with deactivation of mTOR and ERK1/2 pathways in hyperglycemic rats. Sirolimus 39-48 mechanistic target of rapamycin kinase Rattus norvegicus 84-88 31564412-3 2019 Therefore, we wanted to explore specifically the capacity of an mTOR inhibitor, rapamycin, in preventing post-ischemic seizures in hyperglycemic rats and to explore the underlying molecular mechanisms. Sirolimus 80-89 mechanistic target of rapamycin kinase Rattus norvegicus 64-68 31564412-9 2019 Rapamycin treatment completely blocked mTOR activation. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 39-43 31564412-11 2019 We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling. Sirolimus 160-169 mechanistic target of rapamycin kinase Rattus norvegicus 126-130 31564412-11 2019 We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling. Sirolimus 160-169 mechanistic target of rapamycin kinase Rattus norvegicus 248-252 31534118-8 2019 Following that, we use Rapamycin and MK-2206 to inhibit the Akt/mTOR signaling pathway, meanwhile, Rattus 4EBP1, p70S6K, Akt1 and Akt2 were transfected to H9C2 cells to establish the stably transfected cell lines. Sirolimus 23-32 mechanistic target of rapamycin kinase Rattus norvegicus 64-68 31057050-6 2019 The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment. Sirolimus 113-122 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 31057050-11 2019 In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway. Sirolimus 61-70 mechanistic target of rapamycin kinase Rattus norvegicus 135-139 31517703-3 2019 OBJECTIVE: To investigate whether surgery activates the mTOR signaling pathway in aged rats, leading to PND, and whether the mTOR inhibitor, rapamycin, can be used to alleviate PND. Sirolimus 141-150 mechanistic target of rapamycin kinase Rattus norvegicus 125-129 31517703-10 2019 CONCLUSIONS: Our results indicate that an altered mTOR signaling pathway after a splenectomy causes PND in aged rats, which can be alleviated by rapamycin. Sirolimus 145-154 mechanistic target of rapamycin kinase Rattus norvegicus 50-54 31257459-13 2019 As a specific inhibitor of mTOR, rapamycin effectively attenuated the effects of E2. Sirolimus 33-42 mechanistic target of rapamycin kinase Rattus norvegicus 27-31 30953772-0 2019 Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin. Sirolimus 101-110 mechanistic target of rapamycin kinase Rattus norvegicus 86-90 30474386-11 2019 The sirolimus mesh markedly suppressed MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC migration, and reduced phospho-mTOR levels. Sirolimus 4-13 mechanistic target of rapamycin kinase Rattus norvegicus 152-156 30838711-6 2019 LY294002 and rapamycin were added to inhibit the PI3K/AKT pathway and mTOR pathway, respectively. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 70-74 30032425-10 2019 Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 30684510-10 2019 Suppression of mTOR by rapamycin treatment reduced the increase in peak glucose hypermetabolism in muscle denervation. Sirolimus 23-32 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 30032425-10 2019 Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 77-81 30447474-12 2019 Importantly, blocking oxidative stress with VE or blocking Akt/mTOR with rapamycin mitigated the exacerbation of AITD and the suppression of normal autophagy. Sirolimus 73-82 mechanistic target of rapamycin kinase Rattus norvegicus 63-67 30553049-0 2019 Rapamycin administration during normal and diabetic pregnancy effects the mTOR and angiogenesis signaling in the rat placenta. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 74-78 30628698-6 2019 Beclin-1, phosphorylated (p)-protein kinase B (Akt), p-glycogen synthase kinase (GSK)3beta and p-mechanistic target of rapamycin (mTOR) expression was also measured in the following PC12 cell groups: Control group, model group, 3-methyladenine group (5 nM), rapamycin group (100 nM) and galangin group (1 microg/ml). Sirolimus 119-128 mechanistic target of rapamycin kinase Rattus norvegicus 130-134 29962282-0 2019 Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer"s disease lesion in hippocampus of rats with type 2 diabetes mellitus. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 38-42 29962282-3 2019 This study aims to investigate effects of rapamycin on AD in hippocampus of T2DM rat by AMPK/mTOR signaling pathway. Sirolimus 42-51 mechanistic target of rapamycin kinase Rattus norvegicus 93-97 29962282-8 2019 RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR. Sirolimus 28-37 mechanistic target of rapamycin kinase Rattus norvegicus 335-339 29962282-8 2019 RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR. Sirolimus 28-37 mechanistic target of rapamycin kinase Rattus norvegicus 362-366 29962282-9 2019 CONCLUSION: The study demonstrated that rapamycin reduces the risk of AD in T2DM rats and inhibits activation of AMPK-mTOR signaling pathway, thereby improving AD lesion in hippocampus of T2DM rats. Sirolimus 40-49 mechanistic target of rapamycin kinase Rattus norvegicus 118-122 29869197-10 2019 Intracerebroventricular injection of the TrkB antagonist, K252a (0.05 nmol/muL), or the mTOR inhibitor, rapamycin (1 nmol/muL), abolished the behavioral effects of CBD. Sirolimus 104-113 mechanistic target of rapamycin kinase Rattus norvegicus 88-92 30584274-5 2018 Rats were treated with curcumin (200 mg/kg) and the mTOR inhibitor rapamycin (2.5 mg/kg) daily for 3 weeks. Sirolimus 67-76 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 30325723-8 2019 Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in paclitaxel rats (P < 0.05 vs. without rapamycin). Sirolimus 20-29 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 30325723-8 2019 Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in paclitaxel rats (P < 0.05 vs. without rapamycin). Sirolimus 121-130 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 30346929-6 2018 We found that rapamycin significantly enhanced DE development through mTOR suppression-induced augmentation of macrophage autophagy, while CQ significantly decreased DE development through suppression of macrophage autophagy. Sirolimus 14-23 mechanistic target of rapamycin kinase Rattus norvegicus 70-74 29928901-0 2018 Rapamycin mediates mTOR signaling in reactive astrocytes and reduces retinal ganglion cell loss. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 30200803-0 2018 The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 113-117 30200803-10 2018 The expression levels of mTOR and S6K1 increased and LC3II expression decreased in the renal tissues of the DN and RAPA groups compared with the NC group (p < .05). Sirolimus 115-119 mechanistic target of rapamycin kinase Rattus norvegicus 25-29 30050390-7 2018 Expectedly, rapamycin decreased the activity of the mTOR pathway in both sham-operated rats (p < 0.0001) and CLP rats (p < 0.01). Sirolimus 12-21 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 30224017-18 2018 Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 30224017-18 2018 Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 67-71 30224017-18 2018 Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 67-71 29803175-10 2018 Rapamycin, an inhibitor of mTOR, reversed the effect of LPS on rat intestine epithelial cells. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 27-31 29675586-0 2018 Rapamycin Alleviates Hormone Imbalance-Induced Chronic Nonbacterial Inflammation in Rat Prostate Through Activating Autophagy via the mTOR/ULK1/ATG13 Signaling Pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 134-138 29675586-9 2018 In addition to some histological changes in the prostate tissues, we found the levels of NF-kappaB and IL-1beta were significantly increased in the model group, along with significantly suppressed autophagy, whereas rapamycin could reverse these effects which involved in the mTOR/ULK1/ATG13 signaling pathway. Sirolimus 216-225 mechanistic target of rapamycin kinase Rattus norvegicus 276-280 30132043-6 2018 Pharmacologic inhibition of mTOR signaling using rapamycin (20 nM), FK506 (5 nM), or 4EGI-1 (1 microM), and siRNA knockdown of mTOR, or the mTOR complex binding proteins, raptor or rictor, blocked PCB 95-induced dendritic growth. Sirolimus 49-58 mechanistic target of rapamycin kinase Rattus norvegicus 28-32 29277549-5 2018 Pretreatment of the cells with rapamycin ameliorated oxidative stress, reduced the number of apoptotic cells induced by HG and caused the downstream effects of mTOR activation. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 160-164 29277549-8 2018 mTOR inhibitor rapamycin treatment prevented these changes further alleviated albuminuria and improved renal function. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 29444470-13 2018 In conclusion, sirolimus significantly improved hepatic inflammation and fibrosis accompanied by portal pressure reduction in cirrhotic rats, in which down-regulated mTOR/P70S6K and up-regulated eNOS expressions might play a role. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 166-170 29904395-0 2018 Rapamycin provides anti-epileptogenic effect in a rat model of post-traumatic epilepsy via deactivation of mTOR signaling pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 107-111 29757673-5 2018 Results indicated that both rapamycin and AZD8055 inhibited mTOR complex 1 (mTORC1)/70-kDa ribosomal protein S6 kinase signaling similarly, whereas mTORC1/eukaryotic translation initiation factor 4E-binding protein 1 signaling was greatly inhibited by AZD8055. Sirolimus 28-37 mechanistic target of rapamycin kinase Rattus norvegicus 60-64 29240812-9 2017 In addition, vaspin increased the phosphorylation levels of mTOR and p70S6K, which was inhibited by rapamycin. Sirolimus 100-109 mechanistic target of rapamycin kinase Rattus norvegicus 60-64 29468175-9 2018 Rapamycin pre or postadministration inhibited the overactivation of mTOR pathway in ischemic penumbra. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 68-72 29468175-13 2018 mTOR inhibitor rapamycin significantly decreased the mTOR activation and infarct volume and subsequently improved neurological function. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 29468175-13 2018 mTOR inhibitor rapamycin significantly decreased the mTOR activation and infarct volume and subsequently improved neurological function. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 53-57 29540670-5 2018 Rapamycin, an mTOR inhibitor, restored myocardial apoptosis in the presence of beta1-AABs. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 29893708-1 2018 INTRODUCTION AND AIM: To investigate the effect of mTOR inhibitor Rapamycin combined with transcatheter arterial embolization (TAE) on the growth, metastasis, and prognosis of hepatocellular carcinoma (HCC) in rat model. Sirolimus 66-75 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 29996117-9 2018 Blocking mTOR by intrathecal infusion of rapamycin attenuated mechanical pain and cold hypersensitivity. Sirolimus 41-50 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 30257237-14 2018 The mTOR inhibitor rapamycin induced autophagy and decreased cardiomyocyte apoptosis, but the autophagy inhibitor 3-MA decreased autophagy and increased apoptosis at 3 h after exposure to hypoxia and H2O2. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 27133527-9 2018 Rapamycin fully abolished PA or 5-HT-induced mTOR activation, which was more effective than sarpogrelate. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 45-49 28765938-6 2017 Immunohistochemistry of mechanistic target of rapamycin (mTOR) and Ki67 in testes tissue, and western blotting of phosphorylated-p70S6K and p70S6K, supported the hypothesis that rapamycin causes sperm reduction through inhibiting proliferation of spermatogonia. Sirolimus 46-55 mechanistic target of rapamycin kinase Rattus norvegicus 57-61 28669853-0 2017 Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients. Sirolimus 10-19 mechanistic target of rapamycin kinase Rattus norvegicus 109-113 27660271-5 2017 Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1). Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 59-63 28801605-7 2017 Furthermore, we found that pretreatment with the mTOR inhibitor, rapamycin, significantly reduced the expression of the pro-apoptotic protein Bax. Sirolimus 65-74 mechanistic target of rapamycin kinase Rattus norvegicus 49-53 29085189-8 2017 When the intracellular pathway mTOR/S6k was inactivated by chronic treatment with rapamycin, rimonabant treatment was no longer able to stimulate the gastric secretion of Nucb2/nesfatin-1. Sirolimus 82-91 mechanistic target of rapamycin kinase Rattus norvegicus 31-35 28229367-0 2017 Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 28475806-0 2017 Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 90-94 28475806-9 2017 CONCLUSIONS: Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the CA-JV shunt-induced PAH model in rats. Sirolimus 13-22 mechanistic target of rapamycin kinase Rattus norvegicus 103-107 28656223-0 2017 Rapamycin inhibits CaCl2-induced thoracic aortic aneurysm formation in rats through mTOR-mediated suppression of proinflammatory mediators. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 84-88 28656223-4 2017 Without pre-administering rapamycin, significantly enhanced phosphorylation of mTOR and expression of proinflammatory cytokines [i.e., tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and interleukin (IL)-1beta] were observed in the CaCl2-treated aortic segments 2 days post-treatment compared with the NaCl-treated segments. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 79-83 28656223-7 2017 Further in vitro cell culture experiments using aortic smooth muscle cell (SMC) suggested that the inhibition of the mTOR signaling pathway by rapamycin could promote the differentiation of SMCs, as reflected by the reduced expression of S100A4 and osteopontin. Sirolimus 143-152 mechanistic target of rapamycin kinase Rattus norvegicus 117-121 28656223-8 2017 The present study indicated that the early enhanced mTOR signaling pathway in the TAA development and mTOR inhibitor rapamycin may inhibit CaCl2-induced TAA formation. Sirolimus 117-126 mechanistic target of rapamycin kinase Rattus norvegicus 102-106 28404768-5 2017 AAV9 (adeno-associated virus 9)-mediated cardiac DJ-1 overexpression as well as pretreatment with the autophagy inducer rapamycin restored IPO-induced cardioprotection in diabetic rats, an effect accompanied by AMPK/mTOR activation and autophagy up-regulation. Sirolimus 120-129 mechanistic target of rapamycin kinase Rattus norvegicus 216-220 28729914-5 2017 Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus. Sirolimus 20-29 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 28199961-1 2017 We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 72-103 28199961-1 2017 We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 105-109 28625574-6 2017 In half of the rats, an mTOR inhibitor, rapamycin was given for 2days before MCA occlusion. Sirolimus 40-49 mechanistic target of rapamycin kinase Rattus norvegicus 24-28 28808420-9 2017 Inhibition of mTOR with rapamycin ameliorated the damage and suppressed hyperglycemia-elevated p-MTOR, p-P70S6K and p-S6. Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 28808420-9 2017 Inhibition of mTOR with rapamycin ameliorated the damage and suppressed hyperglycemia-elevated p-MTOR, p-P70S6K and p-S6. Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 97-101 28229367-12 2017 Inhibition of the mTOR pathway by rapamycin may be a potential therapeutic approach for pharmacoresistant epilepsy. Sirolimus 34-43 mechanistic target of rapamycin kinase Rattus norvegicus 18-22 29224002-15 2017 The effects of U50,488H on PASMC autophagy were inhibited by AICAR, a selective AMPK agonist, or by rapamycin, a selective mTOR inhibitor. Sirolimus 100-109 mechanistic target of rapamycin kinase Rattus norvegicus 123-127 28108221-10 2017 Rapamycin, a specific mTOR inhibitor, counteracted the Resv-induced cell enlargement (both cell diameter and area). Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 22-26 27888418-10 2017 Suppression of mTOR signaling pathway by rapamycin could promote BMSCs differentiation into osteoblast in DS. Sirolimus 41-50 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 26588882-0 2017 mTOR inhibition by rapamycin protects against deltamethrin-induced apoptosis in PC12 Cells. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 27780878-4 2016 Blocking mTOR by intrathecal infusion of rapamycin attenuated bladder hyperactivity and pain. Sirolimus 41-50 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 28123835-6 2016 Blocking mTOR by using rapamycin selectively enhanced activities of IL-6 and TNF-alpha signaling pathways, which was accompanied with an increase of Caspase-3, indicating cellular apoptosis and worsened learning performance. Sirolimus 23-32 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 27371338-2 2016 Rapamycin inhibits mTOR activity, thereby preventing the phosphorylation of ribosomal protein S6, which is a downstream target of S6 kinase. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 27555230-3 2016 In euvolemic anaesthetized rats, treatment with the mTOR inhibitor rapamycin increased blood pressure (121 +- 2 to 144 +- 3 mmHg; P<.05), decreased glomerular filtration rate (GFR; 1.6 +- 0.3 to 0.5 +- 0.2 mL/min; P<.05) and increased urinary sodium excretion (UNaV; 14 +- 1 to 109 +- 25 mmol/L per hour; P<.05). Sirolimus 67-76 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 27555230-4 2016 In rats subjected to IR, autophagy induction, p-mTOR expression and serum creatinine increased (1.9 +- 0.2 to 3 +- 0.3 mg/dL; P<.05); treatment with rapamycin blunted p-mTOR expression but further increased autophagy induction and serum creatinine (3 +- 0.3 to 5 +- 0.6 mg/dL; P<.05). Sirolimus 152-161 mechanistic target of rapamycin kinase Rattus norvegicus 48-52 27555230-4 2016 In rats subjected to IR, autophagy induction, p-mTOR expression and serum creatinine increased (1.9 +- 0.2 to 3 +- 0.3 mg/dL; P<.05); treatment with rapamycin blunted p-mTOR expression but further increased autophagy induction and serum creatinine (3 +- 0.3 to 5 +- 0.6 mg/dL; P<.05). Sirolimus 152-161 mechanistic target of rapamycin kinase Rattus norvegicus 172-176 27755955-5 2016 Western blot analysis showed that ICH led to a long-lasting increase of phosphorylated mTOR and this hyperactivation of mTOR was reduced by systemic administration of rapamycin. Sirolimus 167-176 mechanistic target of rapamycin kinase Rattus norvegicus 87-91 27755955-5 2016 Western blot analysis showed that ICH led to a long-lasting increase of phosphorylated mTOR and this hyperactivation of mTOR was reduced by systemic administration of rapamycin. Sirolimus 167-176 mechanistic target of rapamycin kinase Rattus norvegicus 120-124 26374551-7 2016 However, much lower levels of phospho-mTOR, phospho-p70S6K, and AChE expression occurred in both brain regions of diabetic rats treated with rapamycin when compared with untreated ones. Sirolimus 141-150 mechanistic target of rapamycin kinase Rattus norvegicus 38-42 27343825-6 2016 Rapamycin treatment suppressed the effect of VPA on mTOR signaling and ameliorated the autistic-like behaviors of rats in our autism model. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 27564518-8 2016 Retinal MCs in HG treated with rapamycin (mTOR inhibitor) show autophagy machinery activation and reestablishment of cargo degradation, protecting cells from apoptosis (P < 0.0001). Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 27423593-6 2016 Rapamycin and AZD8055 were also used to demonstrate the mTOR"s role on microglial polarization in vitro. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 56-60 27423593-8 2016 Rapamycin or AZD8055 markedly decreased the phosphorylation levels of mTOR and its substrates and the activation of microglia in vivo, and promoted the microglial polarization from M1 phenotype to M2 phenotype. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 70-74 27423593-10 2016 Our findings suggested that the rapamycin and AZD8055 could attenuate the development of EBI in this SAH model, possibly through inhibiting the activation of microglia by mTOR pathway. Sirolimus 32-41 mechanistic target of rapamycin kinase Rattus norvegicus 171-175 27235551-9 2016 This effect could be reversed by rapamycin, an inhibitor of mTOR. Sirolimus 33-42 mechanistic target of rapamycin kinase Rattus norvegicus 60-64 26946108-8 2016 Furthermore, the intrathecal administration of rapamycin, inhibiting the activity of mTOR, suppressed the phosphorylation of DRG Nav1.8, reduced the TTX-R current density, heightened the voltage threshold for activation and lowered the voltage threshold for inactivation and relieved mechanical hypersensitivity in diabetic rats. Sirolimus 47-56 mechanistic target of rapamycin kinase Rattus norvegicus 85-89 27217700-13 2016 Rapamycin treatment significantly increased contractile force and myocardial localization of phosphorylated-mTOR and decreased cardiac TNF-alpha concentration compared to cirrhotic rats with no treatment. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 108-112 27217700-15 2016 Rapamycin normalized the inotropic effect and altered phosphorylated-mTOR expression and myocardial localization in cirrhotic rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 69-73 27489506-0 2016 Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 95-99 27489506-7 2016 It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings. Sirolimus 150-159 mechanistic target of rapamycin kinase Rattus norvegicus 142-146 27489506-7 2016 It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings. Sirolimus 150-159 mechanistic target of rapamycin kinase Rattus norvegicus 142-146 27261605-8 2016 The treatment of mTOR inhibitor rapamycin prevented against the increase of cytokines expression and hippocampal neuron apoptosis induced by PTZ. Sirolimus 32-41 mechanistic target of rapamycin kinase Rattus norvegicus 17-21 27111854-8 2016 Rapamycin treatment led to the rapid accumulation of autophagic bodies and autophagy lysosomes, decreased p62 protein levels, and increased the ratio of microtubule-associated protein light chain 3 II (LC3-II) to LC3-I in hippocampal neurons through the mTOR signaling pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 254-258 26566757-4 2016 Blocking spinal mTOR by using rapamycin significantly attenuated activities of PI3K signaling pathways as well as mechanical and thermal hyperalgesia. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 16-20 26648565-13 2016 Treatment with rapamycin, an inhibitor of the mTOR/STAT3 signaling pathway had a similar effect to that of NogoA knockdown in the MPP+-treated PC12 cells. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 46-50 27113190-7 2016 CONCLUSION: The mechanism by which rapamycin inhibits the proliferation of valvular interstitial cells probably involves suppression of mTOR to lower S6 and P70S6K phosphorylation level but not direct regulation of the cell cycle. Sirolimus 35-44 mechanistic target of rapamycin kinase Rattus norvegicus 136-140 26734934-0 2016 Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 107-111 26734934-9 2016 mTOR blockade by rapamycin profoundly ameliorated splenomegaly by limiting lymphocytes proliferation, angiogenesis, fibrogenesis and inflammation as well as decreasing portal pressure. Sirolimus 17-26 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 26825372-7 2016 We also determined the effects on METH-induced autophagy and apoptosis after silencing DDIT4 expression with synthetic siRNA with or without pretreatment of a mTOR inhibitor rapamycin in cardiomyocytes using Western blot analysis, fluorescence microscopy and TUNEL staining. Sirolimus 174-183 mechanistic target of rapamycin kinase Rattus norvegicus 159-163 27239444-3 2016 The phosphorylation of p70 S6 kinase, which indicates mTOR activation, was induced in the skin of rats fed a high-fat diet, but this abnormality was reversed by supplementation with rapamycin. Sirolimus 182-191 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 26463951-9 2016 Early inhibition of mTOR by rapamycin improved long-term outcomes in rats. Sirolimus 28-37 mechanistic target of rapamycin kinase Rattus norvegicus 20-24 27776426-7 2016 Pretreatment of young SHRs with the mTOR inhibitor rapamycin blocked the antiautophagic and vasodilative effects of TSG. Sirolimus 51-60 mechanistic target of rapamycin kinase Rattus norvegicus 36-40 27776426-8 2016 Moreover, TSG significantly activated Akt-mTOR signaling in HUVECs and reduced the autophagic levels in vitro, which were almost completely blocked by rapamycin. Sirolimus 151-160 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 27997905-7 2016 Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways. Sirolimus 23-32 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 26691904-2 2016 Treatment with the mTOR inhibitor rapamycin after status epilepticus reduces the development of epilepsy in a rat model. Sirolimus 34-43 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 27493704-10 2016 Rapamycin, an mTOR inhibitor, increased GRP78/BiP and EDC3 levels in a dose-dependent manner and subsequently resulted in a decrease in intracellular production of insulin. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 26622487-9 2015 Rapamycin affected the mTOR signaling pathway in rats following fracture, as indicated by the inhibition of the phosphorylation of ribosomal protein S6, a target of mTOR, and activation of microtubule-associated protein 2 light chain 3, a key marker of autophagy. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 165-169 26297427-13 2015 In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN. Sirolimus 98-107 mechanistic target of rapamycin kinase Rattus norvegicus 23-27 26681922-0 2015 Inhibition of mTOR Pathway by Rapamycin Reduces Brain Damage in Rats Subjected to Transient Forebrain Ischemia. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 26681922-4 2015 Inhibition of mTOR by rapamycin markedly reduced ischemia-induced damage; suppressed p-Akt, p-mTOR, p-P70S6K and p-S6 protein levels; decreased LC3-II and Beclin-1; and prevented cytochrome c release in the two structures. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 26681922-4 2015 Inhibition of mTOR by rapamycin markedly reduced ischemia-induced damage; suppressed p-Akt, p-mTOR, p-P70S6K and p-S6 protein levels; decreased LC3-II and Beclin-1; and prevented cytochrome c release in the two structures. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 94-98 26622487-9 2015 Rapamycin affected the mTOR signaling pathway in rats following fracture, as indicated by the inhibition of the phosphorylation of ribosomal protein S6, a target of mTOR, and activation of microtubule-associated protein 2 light chain 3, a key marker of autophagy. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 23-27 26239133-4 2015 Inhibition of mTOR by rapamycin was found to reduce primarily the immunoproteasome in both H9c2 cells in vitro and mouse heart in vivo, without significant effect on the constitutive proteasome and protein ubiquitination. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 26224775-9 2015 Rats were pretreated with intrathecal injections of 20% DMSO (vehicle controls) or rapamycin (0.1 mM, 12 mul), a selective mTOR complex 1 inhibitor. Sirolimus 83-92 mechanistic target of rapamycin kinase Rattus norvegicus 123-127 26313913-3 2015 We report that rapamycin, an mTOR inhibitor, restored cardiac function in a passively beta1-AAB-immunized rat model with decreased cardiac function and myocardial autophagic flux. Sirolimus 15-24 mechanistic target of rapamycin kinase Rattus norvegicus 29-33 26048361-9 2015 Phosphorylation of mTOR and S6K1 was similar in the two groups and equally reduced by rapamycin. Sirolimus 86-95 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 26048361-10 2015 Thus, a rapamycin-sensitive, mTOR-dependent but S6K1-independent, signal led to enhanced oxidative metabolism in the Eker brain. Sirolimus 8-17 mechanistic target of rapamycin kinase Rattus norvegicus 29-33 26164831-8 2015 Rapamycin was administered to block mTOR activity. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 36-40 26248290-4 2015 Thus, a suitable dose of rapamycin which can maintain the normal function of mTOR and has fewer side effects ideally should be identified. Sirolimus 25-34 mechanistic target of rapamycin kinase Rattus norvegicus 77-81 26248290-6 2015 Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 148-152 26248290-6 2015 Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway. Sirolimus 100-109 mechanistic target of rapamycin kinase Rattus norvegicus 148-152 25924882-14 2015 We conclude that the mTOR pathway in liver serves distinct physiological roles in the adult and fetus, with the latter representing a condition of rapamycin resistance. Sirolimus 147-156 mechanistic target of rapamycin kinase Rattus norvegicus 21-25 26120832-5 2015 Rapamycin was used to treat rats as an mTOR inhibitor. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 39-43 25349217-14 2015 However, rapamycin upregulated p27(Kip1) at least in part via AKT (also known as protein kinase B)/mTOR. Sirolimus 9-18 mechanistic target of rapamycin kinase Rattus norvegicus 99-103 25256739-0 2014 Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 12-16 26150775-8 2015 A single injection of sarcosine exhibited antidepressant-like effects in rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment. Sirolimus 190-199 mechanistic target of rapamycin kinase Rattus norvegicus 115-119 26150775-8 2015 A single injection of sarcosine exhibited antidepressant-like effects in rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment. Sirolimus 190-199 mechanistic target of rapamycin kinase Rattus norvegicus 175-179 26390657-4 2015 With the intervention of mammalian target of rapamycin mTOR inhibitor rapamycin (100 nmol x L(-1)) , the effect of blocking mTOR signaling pathway on autophagic inhibition of emodin was observed. Sirolimus 45-54 mechanistic target of rapamycin kinase Rattus norvegicus 55-59 25034463-7 2015 We measured the activity of mammalian target of rapamycin (mTOR) in the pilocarpine rat model pretreated with the mTOR-specific inhibitor, rapamycin, and SB-399885 using western blotting. Sirolimus 48-57 mechanistic target of rapamycin kinase Rattus norvegicus 114-118 25440763-1 2015 OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model. Sirolimus 230-239 mechanistic target of rapamycin kinase Rattus norvegicus 37-41 25440763-1 2015 OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model. Sirolimus 230-239 mechanistic target of rapamycin kinase Rattus norvegicus 82-86 25440763-1 2015 OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model. Sirolimus 230-239 mechanistic target of rapamycin kinase Rattus norvegicus 82-86 25440763-1 2015 OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model. Sirolimus 230-239 mechanistic target of rapamycin kinase Rattus norvegicus 82-86 26175092-5 2015 METHODS: Diabetic rats (6 weeks post-streptozotocin (STZ)) were treated with rapamycin to inhibit mTOR or vehicle for 2 additional weeks. Sirolimus 77-86 mechanistic target of rapamycin kinase Rattus norvegicus 98-102 24901414-11 2014 The mTOR inhibitor, rapamycin, significantly blocked these effects on escitalopram, paroxetine and tranylcypromine whereas fluoxetine, sertraline and imipramine effects were not affected. Sirolimus 20-29 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 24889758-2 2014 We have recently demonstrated that mTOR"s inhibition by rapamycin (started before seizure onset), permanently reduces the development of spontaneous absence seizures in WAG/Rij rats, an animal model of absence epilepsy; furthermore, mTOR phosphorylation was increased in adult WAG/Rij rats" cortex, but not other brain areas. Sirolimus 56-65 mechanistic target of rapamycin kinase Rattus norvegicus 35-39 24889758-2 2014 We have recently demonstrated that mTOR"s inhibition by rapamycin (started before seizure onset), permanently reduces the development of spontaneous absence seizures in WAG/Rij rats, an animal model of absence epilepsy; furthermore, mTOR phosphorylation was increased in adult WAG/Rij rats" cortex, but not other brain areas. Sirolimus 56-65 mechanistic target of rapamycin kinase Rattus norvegicus 233-237 24619883-0 2014 PPARgamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. Sirolimus 84-93 mechanistic target of rapamycin kinase Rattus norvegicus 63-67 24976516-9 2014 GFAP and mTOR expression in the rat spinal dorsal horn on post-surgical day 14 was enhanced by daily intrathecal injection of ADP, which was inhibited by rapamycin. Sirolimus 154-163 mechanistic target of rapamycin kinase Rattus norvegicus 9-13 24917666-4 2014 We report that mTOR activation is necessary for BDNF-dependent survival of primary rat hippocampal neurons, as either mTOR inhibition by rapamycin or genetic manipulation of the downstream molecule p70S6K specifically blocked BDNF rescue. Sirolimus 137-146 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 24917666-4 2014 We report that mTOR activation is necessary for BDNF-dependent survival of primary rat hippocampal neurons, as either mTOR inhibition by rapamycin or genetic manipulation of the downstream molecule p70S6K specifically blocked BDNF rescue. Sirolimus 137-146 mechanistic target of rapamycin kinase Rattus norvegicus 118-122 24917666-7 2014 shRNA against the autophagic machinery Atg7 or Atg5 prolonged the survival of neurons co-treated with BDNF and rapamycin, suggesting that suppression of mTOR in BDNF-treated cells resulted in excessive autophagy. Sirolimus 111-120 mechanistic target of rapamycin kinase Rattus norvegicus 153-157 24829408-3 2014 In this study, we injected rapamycin, a mTOR inhibitor, by the intracerebroventricular route 6 h after focal ischemic stroke in rats. Sirolimus 27-36 mechanistic target of rapamycin kinase Rattus norvegicus 40-44 24510654-2 2014 The present study investigates whether rapamycin, an inhibitor of the mTOR pathway, protects against N-methyl-D-aspartate (NMDA)-induced retinal neurotoxicity and whether the extracellular signal-regulated kinase (ERK) pathway contributes to this protective effect in rats. Sirolimus 39-48 mechanistic target of rapamycin kinase Rattus norvegicus 70-74 24619883-1 2014 mTOR inhibition with rapamycin induces a diabetes-like syndrome characterized by severe glucose intolerance, hyperinsulinemia, and hypertriglyceridemia, which is due to increased hepatic glucose production as well as reduced skeletal muscle glucose uptake and adipose tissue PPARgamma activity. Sirolimus 21-30 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 24375611-4 2014 This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin. Sirolimus 137-146 mechanistic target of rapamycin kinase Rattus norvegicus 54-58 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 134-138 24375611-8 2014 The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 151-155 23566837-0 2013 Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 110-114 24586612-4 2014 In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway. Sirolimus 53-62 mechanistic target of rapamycin kinase Rattus norvegicus 212-216 24313960-7 2013 Both elevated mTOR-S6K signaling and enhanced LTP induced by BV injection were reversed by systemic injection of the mTOR inhibitor rapamycin (RAPA). Sirolimus 132-141 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 24313960-7 2013 Both elevated mTOR-S6K signaling and enhanced LTP induced by BV injection were reversed by systemic injection of the mTOR inhibitor rapamycin (RAPA). Sirolimus 132-141 mechanistic target of rapamycin kinase Rattus norvegicus 117-121 23942361-10 2013 The mTOR inhibitor rapamycin blocked the protective effects of both cAkt1 and cAkt3. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 23777415-7 2013 The mTOR inhibitor rapamycin abolished the long-term protective effects of IPostC. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 23777415-11 2013 The mTOR inhibitor rapamycin abolished the long-term protective effects of IPostC. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 24001755-0 2013 Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal. Sirolimus 30-39 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 23827786-5 2013 Rapamycin, known as mTOR inhibitor, was used to inhibit the activation of mTOR, which prevented effectively high glucose-induced SREBP-1 up-regulation and lipogenesis in HKC cells. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 20-24 23827786-5 2013 Rapamycin, known as mTOR inhibitor, was used to inhibit the activation of mTOR, which prevented effectively high glucose-induced SREBP-1 up-regulation and lipogenesis in HKC cells. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 74-78 24695395-9 2014 These effects were prevented by the presence of either melatonin (10 mmol/l) or the inhibitor of mTOR, rapamycin (10 mmol/l). Sirolimus 103-112 mechanistic target of rapamycin kinase Rattus norvegicus 97-101 24602288-5 2014 METHODS: A rat ICH model was induced by intracerebral injection of collagenase IV into the striatum, and mTOR activation was inhibited by administration of rapamycin. Sirolimus 156-165 mechanistic target of rapamycin kinase Rattus norvegicus 105-109 24404143-9 2014 mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Sirolimus 17-26 mechanistic target of rapamycin kinase Rattus norvegicus 0-4 24404143-11 2014 Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Sirolimus 89-98 mechanistic target of rapamycin kinase Rattus norvegicus 29-33 24603476-13 2014 CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats. Sirolimus 110-119 mechanistic target of rapamycin kinase Rattus norvegicus 17-21 24603476-13 2014 CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats. Sirolimus 110-119 mechanistic target of rapamycin kinase Rattus norvegicus 95-99 23566837-7 2013 Western blotting showed decreased expression of phosphorylated mTOR and phosphorylated p70S6K in the rapamycin-treated group, and increased the expression of both SIRT1 and SIRT6 compared to the control group (P<0.05). Sirolimus 101-110 mechanistic target of rapamycin kinase Rattus norvegicus 63-67 23265586-12 2013 Inactivation of mTOR downstream signaling by rapamycin treatment inhibited S6K phosphorylation and abolished the stimulatory effect of IS on GLUT1 expression. Sirolimus 45-54 mechanistic target of rapamycin kinase Rattus norvegicus 16-20 23466691-7 2013 Finally, ethanol self-administration was assessed in rats administered with either memantine or ketamine but pretreated with the mTOR inhibitor rapamycin (2.5mg/kg). Sirolimus 144-153 mechanistic target of rapamycin kinase Rattus norvegicus 129-133 23466691-10 2013 The mTOR inhibitor rapamycin blocked the effects of ketamine, but not those of memantine. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 23313213-1 2013 PURPOSE: Previous molecular studies showed that the mTOR inhibitor rapamycin prevents bladder smooth muscle hypertrophy in vitro. Sirolimus 67-76 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 23667674-0 2013 Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 50-54 23667674-7 2013 These in vivo and in vitro experiments demonstrate that podocyte injury is associated with changes in autophagy levels, and that rapamycin can reduce podocyte injury by increasing autophagy levels via inhibition of the mTOR-ULK1 pathway. Sirolimus 129-138 mechanistic target of rapamycin kinase Rattus norvegicus 219-223 23239524-8 2013 Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration. Sirolimus 20-29 mechanistic target of rapamycin kinase Rattus norvegicus 47-51 23239524-8 2013 Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration. Sirolimus 20-29 mechanistic target of rapamycin kinase Rattus norvegicus 79-83 22684415-0 2013 Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 23-27 22684415-12 2013 The rapamycin group showed significantly decreased CVF (1.87 +- 0.45), accompanied with a significant decrease in mTOR and p70S6K mRNA expression (0.42 +- 0.05 and 0.45 +- 0.04) relative to the Adriamycin group. Sirolimus 4-13 mechanistic target of rapamycin kinase Rattus norvegicus 114-118 23092918-4 2013 Here, we investigated for the first time, the effect of some treatment schedules (i.e. early chronic, sub-chronic and acute) with the specific mTOR inhibitor rapamycin, on the development of absence seizures and seizure parameters as well as depressive-like behavior in WAG/Rij rats, a genetic model of absence epilepsy, epileptogenesis and mild-depression comorbidity. Sirolimus 158-167 mechanistic target of rapamycin kinase Rattus norvegicus 143-147 23699517-8 2013 Inhibition of mTOR with rapamycin reduced axon sprouting. Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 23470622-2 2013 The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin. Sirolimus 192-201 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 23334408-5 2013 The CL316,243-induced activation of p70(S6K) was markedly inhibited by wortmannin, a PI3K inhibitor, and rapamycin, a specific inhibitor of mTOR, suggesting a critical involvement of the PI3K-mTOR-p70(S6K) signaling cascade in the anabolic response of L6 cells to beta3-AR agonist. Sirolimus 105-114 mechanistic target of rapamycin kinase Rattus norvegicus 140-144 23229928-1 2013 BACKGROUND: Use of the mTOR inhibitor (mTORi) sirolimus to replace calcineurin inhibitors in kidney transplantation has been associated with improved renal function but, in a proportion of cases, also with de novo or exacerbated proteinuria. Sirolimus 46-55 mechanistic target of rapamycin kinase Rattus norvegicus 23-27 23852509-5 2013 Control and streptozotocin-induced diabetic rats were treated with the mTOR inhibitor rapamycin (0.2 mg/day) by oral gavage for 14 days, after which mitochondria function was investigated using high-resolution respirometry. Sirolimus 86-95 mechanistic target of rapamycin kinase Rattus norvegicus 71-75 23636065-4 2013 Rapamycin, a kind of mTOR inhibitor upregulating autophagy, was given to rats weeks after the immunization at low (1 mg/kg day i.p. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 21-25 22178316-4 2012 Here we examined the effects of infusions of the mTOR inhibitor rapamycin into the BLA before or after either training or reactivation on retention of novel object recognition (NOR) memory in rats, and compared the effects with those obtained using intra-DH infusions. Sirolimus 64-73 mechanistic target of rapamycin kinase Rattus norvegicus 49-53 23207611-3 2012 We used a new model of experimental chronic pancreatitis to examine the effect of immune modulation with the mTOR-inhibitor rapamycin on clinical, chemical and histological parameters of chronic pancreatitis. Sirolimus 124-133 mechanistic target of rapamycin kinase Rattus norvegicus 109-113 22575459-8 2012 The notion that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK-AKT-mTOR pathway was further suggested by the finding that rapamycin completely abolished the effect of IGF-1 on the 10-pS Cl channels in the TAL. Sirolimus 154-163 mechanistic target of rapamycin kinase Rattus norvegicus 99-103 22266196-4 2012 PI3 kinase inhibition by LY294002 and mTOR inhibition by rapamycin blocked the reversal of the anti-anabolic effects of TNF+IFN-treated myotubes by DAG. Sirolimus 57-66 mechanistic target of rapamycin kinase Rattus norvegicus 38-42 22014210-0 2012 Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Sirolimus 27-36 mechanistic target of rapamycin kinase Rattus norvegicus 8-12 22037516-0 2012 Inhibition of mTOR by rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 22227620-3 2012 Recent data from experimental models pointed to the mTOR pathway, which can be potently inhibited by rapamycin. Sirolimus 101-110 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 22178140-9 2012 Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 44-48 22123082-6 2012 An increase in phosphorylated-S6 (a downstream effector of mTOR) within intermediate grey neurons in Ex rats was blocked by Rapamycin treatment. Sirolimus 124-133 mechanistic target of rapamycin kinase Rattus norvegicus 59-63 21874357-5 2011 Here, we show that pharmacological inhibition of mTOR activity with rapamycin protected INS-1 cells against DN-HNF1A-induced apoptosis. Sirolimus 68-77 mechanistic target of rapamycin kinase Rattus norvegicus 49-53 22067655-3 2011 The results also demonstrated that inhibition of mTOR/p70S6K with rapamycin prevented the development of insulin resistance but had no effect on AMPK activity (Thr172 phosphorylation of its catalytic subunit). Sirolimus 66-75 mechanistic target of rapamycin kinase Rattus norvegicus 49-53 20594757-3 2011 We tested this hypothesis in the rat model of 30% TBSA full thickness burn, using the mTOR inhibitor rapamycin. Sirolimus 101-110 mechanistic target of rapamycin kinase Rattus norvegicus 86-90 21073857-4 2011 Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 98-102 21784900-6 2011 The mTOR inhibitor rapamycin also protected glomeruli, demonstrating that calcium signaling has additional calcineurin-independent components. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 21427787-10 2011 Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone. Sirolimus 94-103 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 20517583-10 2010 Rapamycin treatment reduced the phosphorylation of mTOR and its substrates, p70S6K1 and 4EBP1, confirming mTOR inhibition. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 20801129-6 2011 Rapamycin, a specific mTOR inhibitor, did not alter insulin-induced Akt phosphorylation but significantly inhibited SVV expression (from 6.1+-0.3 to 3.0+-0.15, p<0.05). Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 22-26 20615907-13 2011 Sirolimus-treated PCK rats showed only a minor inhibition of renal mTOR-specific phosphorylation of S6K. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 67-71 20560106-12 2010 Phenylephrine increased the expression of TR alpha 1 in nucleus and this response was abrogated in the case of mTOR inhibition by rapamycin. Sirolimus 130-139 mechanistic target of rapamycin kinase Rattus norvegicus 111-115 21289215-7 2011 Pretreatment the cells with the mTOR inhibitor rapamycin reduced the number of apoptotic cells induced by HG and the downstream effects of mTOR activation noted above. Sirolimus 47-56 mechanistic target of rapamycin kinase Rattus norvegicus 32-36 21289215-7 2011 Pretreatment the cells with the mTOR inhibitor rapamycin reduced the number of apoptotic cells induced by HG and the downstream effects of mTOR activation noted above. Sirolimus 47-56 mechanistic target of rapamycin kinase Rattus norvegicus 139-143 21084384-8 2011 These effects were counteracted by addition of glibenclamide, the action of which was blocked by the mTOR inhibitor rapamycin and the protein kinase A (PKA) inhibitor Rp-8-Br-cAMPs. Sirolimus 116-125 mechanistic target of rapamycin kinase Rattus norvegicus 101-105 20854798-0 2011 Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin. Sirolimus 112-121 mechanistic target of rapamycin kinase Rattus norvegicus 97-101 20854798-1 2011 The mTOR-inhibitor rapamycin is a potent drug used in many immunosuppressive and antiinflammatory therapeutic regimes. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 20727967-4 2011 Pretreatment with the mTOR inhibitor rapamycin, decreased carbachol-induced Ca(2+) release in AR4-2J cells. Sirolimus 37-46 mechanistic target of rapamycin kinase Rattus norvegicus 22-26 20517583-10 2010 Rapamycin treatment reduced the phosphorylation of mTOR and its substrates, p70S6K1 and 4EBP1, confirming mTOR inhibition. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 106-110 20678995-8 2010 We observed the effectiveness of the activated Akt/mTOR/p70S6K signaling pathway in improving locomotor recovery, significantly increasing the expression of nestin, neuronal nuclei (NeuN), neuron specific enolase (NSE), and neurofilament 200 (NF200), and relatively inhibiting excessive reactive astrogliosis after SCI in a rapamycin-sensitive manner. Sirolimus 324-333 mechanistic target of rapamycin kinase Rattus norvegicus 51-55 20389030-7 2010 For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway. Sirolimus 4-13 mechanistic target of rapamycin kinase Rattus norvegicus 85-89 20392814-4 2010 Here, we show that MTOR inhibition by rapamycin increases iodide uptake in TSH-stimulated PCCL3 thyroid cell line, although the effect of rapamycin was less pronounced than PI3K inhibition. Sirolimus 38-47 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 20392814-4 2010 Here, we show that MTOR inhibition by rapamycin increases iodide uptake in TSH-stimulated PCCL3 thyroid cell line, although the effect of rapamycin was less pronounced than PI3K inhibition. Sirolimus 138-147 mechanistic target of rapamycin kinase Rattus norvegicus 19-23 20399760-13 2010 Behavioral study showed that intrathecal mTOR inhibitor, rapamycin, did not affect acute nocicepetive transmission. Sirolimus 57-66 mechanistic target of rapamycin kinase Rattus norvegicus 41-45 20054613-6 2010 PI3-kinase and mTOR were blocked using wortmannin (0.6 mg/kg) or rapamycin (0.25 mg/kg), respectively. Sirolimus 65-74 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 20206401-7 2010 Interestingly, mTOR signaling was overactivated in the spleen of portal hypertensive rats, and mTOR blockade by rapamycin profoundly ameliorated splenomegaly, causing a 44% decrease in spleen size. Sirolimus 112-121 mechanistic target of rapamycin kinase Rattus norvegicus 95-99 20148532-1 2010 Coadministration of the calcineurin inhibitor cyclosporine (CsA) and the mTOR inhibitors sirolimus (SRL) or everolimus (RAD) increases the efficacy of immunosuppression after organ transplantation. Sirolimus 89-98 mechanistic target of rapamycin kinase Rattus norvegicus 73-77 19666112-0 2009 Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 91-95 19818818-5 2010 Similar to the action of the mTOR inhibitor rapamycin, dexamethasone (DEX), a synthetic glucocorticoid, also inhibited the mTOR signaling in the hypothalamic explants. Sirolimus 44-53 mechanistic target of rapamycin kinase Rattus norvegicus 29-33 19818818-5 2010 Similar to the action of the mTOR inhibitor rapamycin, dexamethasone (DEX), a synthetic glucocorticoid, also inhibited the mTOR signaling in the hypothalamic explants. Sirolimus 44-53 mechanistic target of rapamycin kinase Rattus norvegicus 123-127 19666112-1 2009 The mTOR kinase inhibitor rapamycin (sirolimus) is a drug with potent immunosuppressive and antiproliferative properties. Sirolimus 26-35 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 19666112-1 2009 The mTOR kinase inhibitor rapamycin (sirolimus) is a drug with potent immunosuppressive and antiproliferative properties. Sirolimus 37-46 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 19589861-8 2009 Rapamycin blocked activation of P-mTOR, P-S6K1, and P-4EBP1 proteins and significantly reduced the number of proliferating cells in the myometrium of OVX rats. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 34-38 19755425-5 2009 Surprisingly, inhibition of the mTOR protein complex 1 (mTORC1) with rapamycin did not impair LTP maintenance or Arc synthesis nor did it inhibit eIF4F formation or phosphorylation of eIF4E. Sirolimus 69-78 mechanistic target of rapamycin kinase Rattus norvegicus 32-36 19622787-6 2009 Abrogation of S6K activity by the mTOR blocker rapamycin failed to counteract amino acid-induced inhibition of glucose and palmitate oxidation, which therefore was obviously independent of mTOR/S6K signaling (decrease in glucose oxidation by addition of 44 mmol/l amino acids: without rapamycin, -60 +/- 4%; with rapamycin, -50 +/- 13%; NS). Sirolimus 47-56 mechanistic target of rapamycin kinase Rattus norvegicus 34-38 19622772-8 2009 Inhibition of mTOR in female Eker rats with the rapamycin analogue WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity, and size. Sirolimus 48-57 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 19622772-8 2009 Inhibition of mTOR in female Eker rats with the rapamycin analogue WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity, and size. Sirolimus 48-57 mechanistic target of rapamycin kinase Rattus norvegicus 100-104 19397913-8 2009 These morphological and biochemical changes were associated with marked activation of the key growth-promoting mTOR signalling pathway, whose pharmacological inhibition with rapamycin completely blocked cardiac hypertrophy induced by rosiglitazone. Sirolimus 174-183 mechanistic target of rapamycin kinase Rattus norvegicus 111-115 19321761-11 2009 The novel finding that rapamycin decreases hypertension, heart enlargement and mTOR signalling in the heart in PKD rats is reported. Sirolimus 23-32 mechanistic target of rapamycin kinase Rattus norvegicus 79-83 19260063-6 2009 Furthermore, repetitive stretching-induced suppression of muscle atrophy was fully inhibited by rapamycin, a potent inhibitor of mTOR. Sirolimus 96-105 mechanistic target of rapamycin kinase Rattus norvegicus 129-133 18651560-13 2008 Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 102-106 19099400-2 2009 This is enhanced when combined with the immunosuppressive mTOR inhibitor sirolimus. Sirolimus 73-82 mechanistic target of rapamycin kinase Rattus norvegicus 58-62 18486258-2 2008 We reported that sirolimus, an mTOR inhibitor, has antiangiogenic properties in HCC. Sirolimus 17-26 mechanistic target of rapamycin kinase Rattus norvegicus 31-35 18079735-5 2008 Moreover, R18 sensitized BCR-ABL-transformed cells to inhibition with MEK1 inhibitor U0126, Bcl-2 inhibitor GX15-070, or mTOR inhibitor rapamycin. Sirolimus 136-145 mechanistic target of rapamycin kinase Rattus norvegicus 121-125 18667775-6 2008 Expressions of mTOR and eIF-4E mRNA or protein in CVB3-induced myocardial cells were significantly upregulated compared with the control group (P < 0.05), and rapamycin (10 nmol/L) inhibited the upregulation (P < 0.05). Sirolimus 162-171 mechanistic target of rapamycin kinase Rattus norvegicus 15-19 18667775-7 2008 CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis. Sirolimus 12-21 mechanistic target of rapamycin kinase Rattus norvegicus 58-62 18667775-7 2008 CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis. Sirolimus 12-21 mechanistic target of rapamycin kinase Rattus norvegicus 124-128 17389711-4 2007 Pretreatment with rapamycin prevented the feeding-induced phosphorylation of mTOR, eIF4G, and S6K1 but only partially attenuated the shift in 4E-BP1 into the gamma-form. Sirolimus 18-27 mechanistic target of rapamycin kinase Rattus norvegicus 77-81 19099956-5 2008 RESULTS: (1) mTOR/beta-actin ratio was dose-dependently reduced (1 nmol/L, 0.381 +/- 0.022; 10 nmol/L, 0.282 +/- 0.014; 100 nmol/L, 0.263 +/- 0.012 vs. control 1.45 +/- 0.04, all P < 0.05 vs. control) after 48 hours rapamycin treatments and time-dependently reduced after 10 nmol/L rapamycin treatment (24 h, 0.203 +/- 0.021; 48 h, 0.163 +/- 0.022; 72 h, 0.144 +/- 0.013 vs. 0 h, 0.341 +/- 0.022, all P < 0.05 vs.0 h) in CVB 3 infected myocardial fibroblasts. Sirolimus 219-228 mechanistic target of rapamycin kinase Rattus norvegicus 13-17 17537394-4 2007 The insulin-induced increase of the ENT2 mRNA level was blocked by rapamycin (an inhibitor of mTOR) and by cycloheximide (an inhibitor of protein synthesis), whereas neither wortmannin (an inhibitor of PI3K) nor PD98059 (an inhibitor of MEK) affected the insulin action on the ENT2 transcript level. Sirolimus 67-76 mechanistic target of rapamycin kinase Rattus norvegicus 94-98 17537841-8 2007 Glucose- and insulin-regulated NO production was restored in the presence of the AMPK activator, 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside or the mTOR inhibitor rapamycin. Sirolimus 171-180 mechanistic target of rapamycin kinase Rattus norvegicus 156-160 17541736-4 2007 The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin. Sirolimus 135-144 mechanistic target of rapamycin kinase Rattus norvegicus 68-72 17634255-5 2007 Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex. Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 17634255-5 2007 Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex. Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 101-105 18094073-7 2008 However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells. Sirolimus 67-76 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 18094073-7 2008 However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells. Sirolimus 78-87 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 18094032-3 2008 The present study explores the efficacy of low-dose mTOR inhibition by rapamycin in a chronic-progressive model of mesangioproliferative glomerulosclerosis (cGS). Sirolimus 71-80 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 18094032-10 2008 In conclusion, low-dose mTOR inhibition by rapamycin limits the progressive course of anti-thy1-induced renal disease toward chronic glomerulosclerosis, tubulointerstitial fibrosis, and renal insufficiency. Sirolimus 43-52 mechanistic target of rapamycin kinase Rattus norvegicus 24-28 17671379-2 2007 The effect of mTOR blockade by rapamycin in diabetic nephropathy was investigated, but in vivo study of rapamycin treatment in the course of early diabetes is still insufficient. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 17321636-6 2007 Animals were treated with the mTOR inhibitor sirolimus for 4 weeks. Sirolimus 45-54 mechanistic target of rapamycin kinase Rattus norvegicus 30-34 16597691-2 2006 The effect of mTOR blockade by sirolimus (SRL) in diabetic kidney disease in rats was investigated. Sirolimus 31-40 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 17050028-2 2006 We tested the therapeutic potential of the mTOR inhibitor rapamycin in advanced cirrhosis. Sirolimus 58-67 mechanistic target of rapamycin kinase Rattus norvegicus 43-47 15868910-2 2005 Sirolimus is an inhibitor of the cytosolic mTOR-kinase, associated with the phosphoinositide-3-kinase/Akt pathway. Sirolimus 0-9 mechanistic target of rapamycin kinase Rattus norvegicus 43-47 16221708-0 2006 Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Sirolimus 24-33 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 15358595-6 2005 Inhibition of phosphatidylinositol (PI)3-kinase with LY-294002 or mTOR/p70S6K1 with rapamycin reduced [3H]thymidine incorporation by 50%, i.e., to levels comparable to those achieved by addition of either AG-1478 or GM-6001. Sirolimus 84-93 mechanistic target of rapamycin kinase Rattus norvegicus 66-70 15692808-12 2005 In addition, we demonstrated that inhibition of the mTOR pathway with rapamycin can prevent insulin resistance caused by chronic hyperinsulinaemia in liver and muscle. Sirolimus 70-79 mechanistic target of rapamycin kinase Rattus norvegicus 52-56 15604215-9 2005 Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation. Sirolimus 27-36 mechanistic target of rapamycin kinase Rattus norvegicus 14-18 15604215-11 2005 In vitro studies with rapamycin suggest that mTOR/S6K1 overactivation contributes to elevated serine phosphorylation of IRS-1, leading to impaired insulin signaling to Akt in liver and muscle of this dietary model of obesity. Sirolimus 22-31 mechanistic target of rapamycin kinase Rattus norvegicus 45-49 15284343-4 2004 NKCC-mediated (86)Rb(+) influx was enhanced significantly ( approximately 1.6-fold) by acute cell exposure to insulin, but was inhibited significantly by tyrosine kinase inhibitors, wortmannin and rapamycin, consistent with a role for the insulin receptor tyrosine kinase, phosphoinositide 3 (PI3)-kinase and mTOR, respectively, in cotransporter activation. Sirolimus 197-206 mechanistic target of rapamycin kinase Rattus norvegicus 309-313 15557109-14 2005 We conclude that rapamycin-sensitive mTOR activity was critical to tumor progression in the Eker rat model, but rapamycin is unlikely to eradicate all disease as a result of the development of drug resistance. Sirolimus 17-26 mechanistic target of rapamycin kinase Rattus norvegicus 37-41 15339861-1 2004 Co-administration of the calcineurin inhibitor cyclosporine and the mTOR inhibitors sirolimus or everolimus increases the efficacy of immunosuppression after organ transplantation. Sirolimus 84-93 mechanistic target of rapamycin kinase Rattus norvegicus 68-72 15557109-6 2005 Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation. Sirolimus 56-65 mechanistic target of rapamycin kinase Rattus norvegicus 40-44 15557109-6 2005 Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation. Sirolimus 56-65 mechanistic target of rapamycin kinase Rattus norvegicus 94-98 15313464-6 2004 Fasted rats were treated with the mTOR inhibitor, rapamycin, prior to oral administration of leucine. Sirolimus 50-59 mechanistic target of rapamycin kinase Rattus norvegicus 34-38 15313464-7 2004 It was found that rapamycin severely attenuated leucine-induced signaling through mTOR in liver. Sirolimus 18-27 mechanistic target of rapamycin kinase Rattus norvegicus 82-86 15228089-7 2004 The glucose-induced PTB-binding was only inhibited by the mTOR inhibitor rapamycin. Sirolimus 73-82 mechanistic target of rapamycin kinase Rattus norvegicus 58-62 15158453-4 2004 The mTOR inhibitor rapamycin reversed the dephosphorylation of eEF2 induced by CCK, as did treatment with the p38 MAPK inhibitor SB202190, the MEK inhibitor PD98059, and the phosphatase inhibitor calyculin A. Sirolimus 19-28 mechanistic target of rapamycin kinase Rattus norvegicus 4-8 14990989-3 2004 Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR. Sirolimus 154-163 mechanistic target of rapamycin kinase Rattus norvegicus 181-185 12750770-7 2003 The PI 3-kinase inhibitor LY294002 and the mTOR inhibitor rapamycin, but not the MEK1 inhibitor PD98059, could prevent IRS1 changes in oxidized cells. Sirolimus 58-67 mechanistic target of rapamycin kinase Rattus norvegicus 43-47 14660591-5 2004 Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin. Sirolimus 88-97 mechanistic target of rapamycin kinase Rattus norvegicus 46-50 14660591-5 2004 Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin. Sirolimus 88-97 mechanistic target of rapamycin kinase Rattus norvegicus 72-76 14610086-6 2004 In isolated rat hepatocytes, both regulatory amino acids (RegAA) and insulin coordinately activated p70(S6k) phosphorylation, which was completely blocked by rapamycin, an mTOR inhibitor. Sirolimus 158-167 mechanistic target of rapamycin kinase Rattus norvegicus 172-176 12384518-5 2002 In the Eker rat, short-term inhibition of mTOR by rapamycin was associated with a significant tumor response, including induction of apoptosis and reduction in cell proliferation. Sirolimus 50-59 mechanistic target of rapamycin kinase Rattus norvegicus 42-46 12646166-6 2003 The BCAA mixture dose-dependently promoted the production of albumin, with leucine being the major effector half of which was inhibited by the mTOR inhibitor rapamycin. Sirolimus 158-167 mechanistic target of rapamycin kinase Rattus norvegicus 143-147 12384518-7 2002 Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting. Sirolimus 127-136 mechanistic target of rapamycin kinase Rattus norvegicus 43-47 11015466-3 2000 In the second set of experiments, food-deprived rats were injected intravenously with rapamycin (0.75 mg/kg), a specific inhibitor of mTOR, before leucine administration. Sirolimus 86-95 mechanistic target of rapamycin kinase Rattus norvegicus 134-138 10437918-0 1999 The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Sirolimus 79-88 mechanistic target of rapamycin kinase Rattus norvegicus 64-68 10437918-3 1999 In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism. Sirolimus 127-136 mechanistic target of rapamycin kinase Rattus norvegicus 146-150 10437918-3 1999 In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism. Sirolimus 127-136 mechanistic target of rapamycin kinase Rattus norvegicus 155-159